Loading...
By Amy Orciari Herman
Edited by Susan Sadoughi, MD, and André Sofair, MD, MPH
Products containing the angiotensin-receptor blocker (ARB) valsartan are in short supply because of recent recalls over the drugs containing two probable carcinogens — N-nitrosodimethylamine (NDMA) and N-nitrosodiethylamine (NDEA) — and "other types of products may fall into shortage soon," FDA officials said on Friday.
The agency has established interim acceptable intake levels for NDMA and NDEA, with the aim "to balance the risk of patients ingesting low levels of the impurities ... for a short period of time with the risk that there is a shortage of certain ARBs."
The FDA believes that NDMA-tainted valsartan has been on the market for 4 years — and that if 8000 patients took the highest recommended valsartan dose for that long, one additional cancer would occur. Officials said the "vast majority" of patients were exposed to much lower levels of NDMA. They are still researching the risk posed by NDEA.
NDMA and NDEA appear to be generated during the manufacturing process. Not all ARBs contain these impurities, the FDA noted.
Comment
LINK(S):
FDA statement (Free)
Interim acceptable intakes of NDMA and NDEA (Free)
Background: Recent Physician's First Watch coverage of ARBs and NDEA (Free)